M.M. ALEYEVA¹, E.V. URAKOVA², R.V. LEKSIN¹

¹Republic Clinical Hospital of the MH of RT, 138A Orenburgskiy Trakt, Kazan, Russian Federation, 420139

²Kazan State Medical Academy — Branch Campus of the RMACPE MOH Russia, 36 Butlerov Str., Kazan, Russian Federation, 420012

 Aleyeva M.M. ― stomatologist-therapist, maxillofacial surgeon, tel.: (843) 554-54-25, +7-937-616-79-99, e-mail: [email protected]

Urakova E.V. ― Cand. Med. Sc., Associate Professor of the Department of Maxillofacial Surgery and Surgical Stomatology, tel.: (843) 231-21-10, +7-917-273-65-01, e-mail: [email protected]

Leksin R.V. ― Head of the Department of Maxillofacial Surgery, tel.: (843) 231-21-10, +7-987-296-89-57, e-mail: [email protected]

 Bisphosphonate drugs can be used to prevent and treat osteoporosis and to reduce symptoms and complications of metastatic bone disease (oncological diseases, multiple myeloma), as well as in diseases such as Paget’s disease and malignant hypercalcemia. However, they are associated with a rare but serious adverse event: osteonecrosis of the maxillary and mandibular bones. This condition is called bisphosphonate-related osteonecrosis of the jaw or BRONJ. The article presents risk factors for this pathology, its clinical manifestations, criteria for diagnosis and treatment.

Key words: bisphosphonates, osteonecrosis, maxilla, mandibule, concomitant diseases.

REFERENCES

1. Kaprin A.D., Starinskij V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’), 2017, pp. 3-4.
2. Polyakov K.A., Medvedev Yu.A., Omelchenko A.S. Bisfosfonatnyie osteonekrozyi chelyustey: aspektyi patogeneza i klinicheskie proyavleniya. Head and Neck/Golova i sheya, 2013, Rossiyskoe izdanie №2, pp. 20 – 23
3. G. Anikin, Toropcova N.V. Bisfosfonaty: chto my znaem o nezhelatel’nyh javlenijah, svjazannyh s ih primeneniem. FARMATEKA dlja praktikujushhih vrachej, 2012, no. 19. pp. 81 – 87.
4. Victoria R., Alexandra L., Laura CI MacDonald, Tanya W., Martin R.T., Nicole B Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ), B Vogt-Ferrier Editorial Group: Cochrane Oral Health Group Published Online, 2016.
5. Medvedev Yu., Basin E. Fosfornye nekrozy chelyustej. Vrach, 2012, no. 1, pp. 21-25.
6. Zaslavskaja N.A. Optimizacija profilaktiki i lechenija bisfosfonatnyh osteonekrozov cheljustej u bol’nyh so zlokachestvennymi novoobrazovanijami. Avtoreferat na soiskanie uchenoj stepeni kandidata medicinskih nauk, 2014. pp. 1-25.
7. Sciubba J., Epstein J. Oral Complications Of Cancer And Its Management. Bisphosphonate-related osteonecrosis of the jaw, 2010, pp. 151-162.